There were just two significant judgments from the Patents Court in July, one dealing with monoclonal antibodies and one in a telecoms FRAND case.
The first case was Takeda UK Ltd v F Hoffmann-La Roche AG (Rev 1)  EWHC 1911 (Pat), where Mr Justice Birss found a Roche patent for a monoclonal antibody to be invalid. The patent had been attacked by Takeda, which sought revocation in order to market its Entyvio product, which is a formulation of vedolizumab.
In the second case, Conversant Wireless Licensing SARL v Huawei Technologies Co., Ltd & Ors  EWHC 1687 (Pat), Mr Justice Arnold concluded that the patent at issue was essential to the relevant telecoms standard (and therefore infringed) based on the doctrine of equivalence set out by the Supreme Court in Actavis v Lilly. But he also concluded that the patent was invalid for added matter.
Beyond the UK, there have been important announcements at the EPO, including revised Rules of Procedure for the Boards of Appeals and two decisions from the Enlarged Board of Appeal.
In Ireland, the Commercial Court issued its first blocking order in a case involving Premier League football matches.
This month’s briefing also includes an update on judicial appointments, details of the UK IPO’s Annual Report and the latest Brexit news.
The IP/IT Briefing is part of the Bloomsbury Law Online Service. The full briefing is available here.